Outlook Therapeutics (NASDAQ:OTLK) Earns Neutral Rating from Chardan Capital
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities researchers at Chardan Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $3.00 price objective on the stock. Chardan Capital’s price objective indicates a potential upside of 76.99% from the stock’s previous close. Other […]
Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities researchers at Chardan Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $3.00 price objective on the stock. Chardan Capital’s price objective indicates a potential upside of 76.99% from the stock’s previous close. Other […]
